

# BEHAVIOUR AND SYMPTOM MAPPING TOOL (BSMT) STEP 1: Screening Record (Complete 1x only)

Health Recor	d Number: Clier	nt Label
Paris ID:	ров: уууу	//mon/dd
Last Name:	First Name:	
PHN:	Gender: Age:	
Phone (H):	Phone (C):	

					Referring Physician: (Last Name, First Name)											
A. INI	TIAL SCREEN				Complete EVERY box Yes (Y) or No (N)											
	RULE OU	UT OTHER CAU	SES			NON	-DRUG INT	ERVENTIONS TRIED								
	Pain				1:1 Time											
	Constipation				Distraction											
	Drug Interactions				Consistent Ca	aregive	rs / Predict	able Routine								
la	Depression				One Step Eas	y to Fo	llow Direc	etions								
Clinical	Chronic Illness – l	Loss of contro	Ī		Flexible Rout	ine PR	N / Reappr	roach Later								
C	Urinary Retention				Eye Contact											
	Vision/Hearing In	npairment			Calm / Slow Approach / Allow Time to Respond											
	Active Infection				Reassurance /											
	Sleep Disorder							/ Noise / Activity)								
	Too Hot or Cold				Quiet Space /											
ıtal	Change in Routine				Music / Pet T	herapy										
Environmental	Boredom / Lack o		Activities		Reminisce											
onr	Changed Room / I				Comments al	out in	terventions	s tried (must be completed):								
vir	Lighting Levels /															
En	Other (please desc	cribe):		ľ												
B. DE	FINE AND DESC	RIBE BEHAV			e EVERY box			I)								
					ND TO ANTIPSY	CHOTIC										
Hoardi				Resist Care		<b></b>		erence to Surroundings								
Wande				nsomnia		<b></b>		or Nervous								
	elf Care	aclimation	11	mpaired Mem	iory		Inappropr	riate Elimination								
Unsoci	ial / Inappropriate v	/ocalization	M	1 TA PERPOND	TO AND IDENCIA	OPTOD										
	Delusions	T A	MA Aggression		TO ANTIPSYCHOTICS Anxiety Agitation											
Theft	Detusions	Grabbing / H		1	Negative Atti		Elopement Attempts									
Parano	nia	Biting / Spit			Repetitive Qu			Constant Requests								
False F		Swearing / S		2	Tearful / Guil			Interfering Behaviour								
		Temper outh		<u>'</u>	Restless/Unse			Pacing								
Н	<b>Iallucinations</b>	Sexually Ag	gressive		Sleep Pattern	Shadowing										
	g Things	Describe be	haviours	(must be com	ıpleted):											
	Things															
Sensor	ry / Picking															
PROF	ESSIONAL NURS	SE SIGNATU	RE				_ DAT	E:								
C. DE	CISION MAKING	y J														
Comp	lete EVERY box Y	es (Y) or No	(N)		If Medication has been prescribed as a Behaviour management intervention											
			(14)		Į	1	nanageme									
	MEDICAL RISE	KS & CONSIDE			In agreement				No							
	isting Parkinson's	KS & CONSIDE				with pr	roposed tre	eatment: Yes	No							
Moven	isting Parkinson's ment Disorder					with pr	roposed tre	eatment: Yes	No 							
Mover Presen	isting Parkinson's nent Disorder t Use of CNS depre	essants	RATIONS			with pr	roposed tre	eatment: Yes	No 							
Mover Presen Presen	isting Parkinson's ment Disorder t Use of CNS depre t Use of Cholinester	essants rase Inhibitors	RATIONS			with pr	roposed tre  (residen	atment: Yes   nt/ family/ guardian)  dication for Use Side	Effects							
Mover Presen Presen	isting Parkinson's nent Disorder t Use of CNS depre	essants rase Inhibitors	RATIONS		Discussed wit	with pr	roposed tre  (residented: Inc.	atment: Yes   nt/ family/ guardian)  dication for Use Side  fficacy and Expected Outco	Effects							
Presen Presen Potenti History	isting Parkinson's ment Disorder t Use of CNS depre t Use of Cholinester ial for Lewy Body I y of CVA	essants rase Inhibitors	RATIONS		Discussed wit	with pr	roposed tre  (residented: Inc.	atment: Yes   nt/ family/ guardian)  dication for Use Side	Effects							
Presen Presen Potenti History	isting Parkinson's ment Disorder t Use of CNS depre t Use of Cholinester ial for Lewy Body I	essants rase Inhibitors	RATIONS		Discussed wit	with pr	(residen	nt/ family/ guardian) dication for Use Side fficacy and Expected Outco ssessment and Monitoring	Effects							
Moven Presen Presen Potenti History Potenti Signifi	isting Parkinson's ment Disorder t Use of CNS depre t Use of Cholinester ial for Lewy Body I y of CVA ial for CVA icant Risk of Hemod	essants rase Inhibitors Dementia dynamic Instab	RATIONS		Discussed wit	with pr	(residen	atment: Yes   nt/ family/ guardian)  dication for Use Side  fficacy and Expected Outco	Effects							
Mover Presen Presen Potenti History Potenti Signifi Severe	isting Parkinson's ment Disorder t Use of CNS depre t Use of Cholinester ial for Lewy Body I y of CVA ial for CVA	essants rase Inhibitors Dementia dynamic Instab	RATIONS		Discussed wit	with pr	(residen	nt/ family/ guardian) dication for Use Side fficacy and Expected Outco ssessment and Monitoring	Effects							

Antipsychotic medications are used to treat a variety of symptoms in psychotic disorders, delusional depression and dementia. In order to identify a change, close monitoring and documentation of behaviors is needed before and during use. Since these medications are not free of side effects, it is important to review the inventory of target behaviors prior to commencing the medication and on a regular basis after the drug treatment is initiated.

#### **Step 1: Initial Screen**

**EVERY** box on the BSMT must be completed with either a "Y" for yes or "N" for no. Absence of documentation (empty boxes) can not be interpreted making review and evaluation of behaviour extremely difficult

**Section A must** be completed for every client as part of a screening process. It is a tool to identify patients suitable to receive antipsychotics and documentation of that decision making process.

\*\*Note: For new admissions already on antipsychotic agents, start with Step 1 then skipping to Step 3. Current residents should have Step 1 completed to establish a base line for behaviours.

- 1. **Rule Out Other Causes:** Any of these clinical or environmental causes may be contributing to the behaviors and can likely be managed by other means than drug therapy. Review any identified possible causes to determine if applicable in this situation. Check yes if symptom is present and no if it is not. Further documentation may be necessary and should be included in the resident's health record.
- 2. **Non-Drug Interventions**. Due to risk of complications of medication, behavioural interventions should always be trialed completely and consistently prior to the consideration of any medicinal interventions. Document responses in comments section.

#### Section B: Define and Describe Behaviour

This section is to guide the health care professional in deciding if the behaviour may or may not be treatable with medication. A clear understanding of behaviour will facilitate this process.

- 1. WILL NOT RESPOND To Antipsychotics. Medications have often been prescribed to manage behaviours for which it may have little or no effect.
- 2. *MAY Respond to Antipsychotics*. In addition to indicating which behaviours are occurring, a narrative description is required to further ensure that the medication is being considered for the appropriate reason and could be feasibly managed by medication.

### Section C: Decision Making – Should be completed by the Physician

*Medical Risks & Considerations*. This section is designed to trigger a review of any medical condition(s) that may increase the risk of adverse events for the patient. The prescriber, upon reviewing the existing medical conditions will determine if the risks preclude the use of antipsychotics.

Due to the potential for significant adverse effects, clear documentation of consent is required. Discussions surrounding usage should occur between the physician and resident/family. It is likely that this section may be completed at a later date than the initial screen once a more thorough assessment has been completed. The assessment data will likely include the initial behaviour mapping.



A. AGITATION

Identify up to three difficult behaviours encountered with the resident in providing care

# **BEHAVIOUR AND SYMPTOM MAPPING TOOL (BSMT)**

# **STEP 2: Assessment Prior to Medication**

	. AGGRESSION L . DELUSIONS [	  -  -								D. I	IALL	UCIN	ATIO	NS	□ .											F	Referrir	ng Physician	: (Last	Name, Fir	st Name)
PAR	Γ A: BEHAVIOURS	-ASS	ESSV	IENT	PRI	OR TO	о мі	EDIC	ATIO	)N																					
	DATE	0020	0080	0060		1100	1200	1300	1400	1500	1600	1700	1800	1900	2000	2100	2200	2300	2400	0100	0200	0300	0400	0200	0090			COM	MENTS		
ONE																															
WEEK																															
W																															
																													V	VEIGHT	
TWO																															
ΚŢ																															
WEEK																															
																													WE	EIGHT	
PAR	Γ B: BASELINE STA	TUS	- PL	ACE	A CI	HECK	MA	RK I	N TH	Е ВО	XES	OF T	HE S	YMP	ГОМ	S TH	AT A	RE I	PRES	ENT	PRIC	OR TO	) STA	ARTI	NG T	THE MEDI	CATIO	N	***	<u></u>	
	TARDIVE DYSKI	NES	[A (e.g	g., inv	olunt	ary	,		1	AGIT	ATIO	ON								C	ONF	USIO	N					CONSTIP	PATION		
	movements, lip sma		_		_		e)		(	CERI	EBRA	L VA	SCUI	LAR A	ACCI	DEN	T/T	IA		D	RY	MOUT	ГН					DEHYDR	ATION		
	DYSTONIA (e.g., 1								]	DRO	WSIN	ESS /	SED	ATIO	N					F	ALL	S						WEIGHT	GAIN (	weight week	ly in kg.)
	EXTRAPYRAMII tremors, drooling, c				MS (e.	.g.,							R UNI				)			C	RTH	IOST	ATIC	HY	POTE	ENSION					-
COM	MENTS:																														
PROF	FESSIONAL NURSE	REVI	EW															DA	TE: _												
DHV	SICIAN/PRESCRIBE	D DE	VIEW		(sign	ature)												DΔ	TF.												
1111	ACH HAT RESCRIBE	I IL	, IL W		(sign	ature)																									
PHAF	RMACIST REVIEW				(sign	ature)												DA	TE: _												
					. 0	- /																									

Health Record Number:

Paris ID:

PHN:

Last Name:

Phone (H):

Client Label

DOB: yyyy/mon/dd

First Name: Gender: Age:

Phone (C):

#### **STEP 2: Assessment Prior to Medication**

It is strongly recommended that two weeks of behavior mapping be documented **prior to initiating any drug therapy** to serve as a baseline. Mapping should be initiated by nursing upon identification of a behavioural concern in order to facilitate any required treatment regimes.

Step 2 mapping is divided into two sections:

- 1. **Behaviours.** Identify the behaviours that may respond to antipsychotic medication and describe how it appears for that resident. Document observed behaviours by putting the letter of the behaviour on the form during the appropriate time period. Boxes are left blank if there are no behaviours. Place any comments in the comments section.
- 2. **Baseline status:** Observe resident for any of the describe symptoms noted by placing a check mark in the appropriate boxes. The comment sections may be used to record additional assessment information necessary to describe dates or times symptoms occurred.

\*\*Note: Resident and staff safety should not be compromised in order to complete two weeks of behaviour mapping if initiation of medication sooner is clinically indicated. In this situation, at least one week of Step 2 should be completed retrospectively while proceeding with Step 3

After two weeks of behavior mapping, the situation will be reviewed by the physician to determine if the presenting behaviors are still within the treatment parameters and the plan for initiating drug therapy should go forth. A section has been designated for the professional nurse, the physician and pharmacist to sign after reviewing. This review of the data at the end of the initial two weeks may occur via fax, phone, or in person. If professional nurses discuss with physician/pharmacist by phone nurse may document as discussed, sign for physician/pharmacist and sign nurse's name.



Identify up to three difficult behaviours encountered with the resident in providing care

# **BEHAVIOUR AND SYMPTOM MAPPING TOOL (BSMT)**

# STEP 3: ASSESSMENT RESPONSE TO MEDICATION

F	A. AGITATION  B. AGGRESSION  F. DELVISIONS										ANX HAL			IONS		] ] 							<del></del>			Refe	rring	Phys	sician:	(L	ast Na	me, Fir	st Nam	e)	
	E. DELUSIONS	Ш-																																	
PAR	T A: BEHAVIOURS	S-ASS	ESSM	IENT	RES	SPON	SE T	O ME	EDIC	ATIO	N					ı		ı	ı																
	DATE	0020	0800	0060	1000	1100	1200	1300	1400	1500	1600	1700	1800	1900	2000	2100	2200	2300	2400	0100	0200	0300	0400	0200	0090				co	ЭММ	ENTS				
男																																			
WEEK ONE																																			
WEE																																			
																															WE	IGHT			_
WO																																			
WEEK TWO																																			
WEE																																			
																															WE	IGHT			
PAR	T B: BASELINE ST	ATUS	5													ļ.			ļ.		-	-													
[mp	ortant Side Effect	s (NE	EW o	r IN	CRE	ASE	D af	fter s	starti	ng m	nedic	ation	or c	chang	ging	dose	) **	* Re	port	to I	Physic	cian													
	TARDIVE DYSKIN movements, lip smack								A	GITA	TIO	N								C	CONFU	JSIO	N					] (	CONST	ГІРА	TION				
	DYSTONIA (e.g., lea	_	_		_				C	EREI	BRAI	VAS	CUL	AR A	CCII	DENT	T/TL	A		D	ORY M	OUT	Ή					] ]	DEHYI	DRA'	TION				
	EXTRAPYRAMIDA						ore.		D	ROW	SINE	SS/S	SEDA	TIO	N					F	ALLS							] '	WEIGH	HT G	AIN (v	weight w	eekly in	kg.)	
	drooling, cogwheeling		IVII I	ONIS	(e.g.,	tienic	515,			XCE8 .g., de					SARY	DISA	ABIL	ITY		C	ORTHO	OSTA	ATIC	HYP	OTE	NSION		-						_	
CON	MMENTS:																																		
PRO	FESSIONAL NURSE	REVI	EW	_																	DATE	E:													
PHY	SICIAN/PRESCRIBE	ERRE	VIEW		sign	ature	)														DATE	l:													
			. 12 11		sign	ature	)																												
PHA	RMACIST REVIEW			(	sign	ature	)														DATE	E:													
					_																														

Health Record Number:

Paris ID:

PHN:

Last Name:

Phone (H):

Client Label DOB: yyyy/mon/dd

First Name:

Gender: Age:

Phone (C):

## STEP 3: Assessment Response to Medication

The purpose of this step is to document an ongoing assessment of the patient **following the commencement of drug therapy**. Step 3 mapping should commence as soon as any drug therapy has begun and continue daily for a minimum of 2 weeks or longer as further medication adjustments are made, until the behavior is resolved or drug therapy is deemed ineffective.

Step 3 is divided into two sections.

- 1. *Behaviours*. Identify the behaviours that may respond to antipsychotic medication and describe how it appears for that resident. Document observed behaviours by putting the letter of the behaviour on the form during the appropriate time period. Boxes are left blank if there are no behaviours. Place any comments in the comments section.
- 2. **Baseline status:** Observe resident for new or increased side effects after staring the medication and note by placing a check mark in the appropriate boxes.

\*\*Note: An observed change in any of these side effects should be reported to physician.

The attending physician or prescriber, professional nurse and clinical pharmacist will review the behavior mapping and clinically assess the effectiveness of the drug therapy to determine if this drug therapy will be continued. If professional nurses discuss with physician/pharmacist by phone nurse may document as discussed, sign for physician/pharmacist and sign nurse's name.



# **Behaviour and Symptom Mapping Tool (BSMT)**

# STEP 4: MONTHLY MAINENTANCE RECORD

Health Record Number: Client Label

DOB: yyyy/mon/dd Paris ID:

First Name: Last Name:

PHN: Gender: Age:

Phone (H): Phone (C):

				Referring P	hvsician: (Last Name. First Name)								
MONITOR T	HE FREQUENCY OF TARGETED BEHAVIOURS. DOCUMENT USIN	G THE SCOR	E THAT 'BE	ST'									
REFLECTS T	THE FREQUENCY OF BEHAVIOURS IN EACH THIRTY (30) DAY PE	RIOD.											
Enter a Numb into EVERY B "0 -4"	1	ı every day	For significant changes in behaviours, commence of mapping using the BSMT  NOTE: Document assessments of behaviours and side effects in progress record.										
	MONTH AND YEAR				COMMENTS (DOES NOT REPLACE MPR)								
	BEHAVIOURS												
	<b>Delusions</b> (paranoia / bizarre ideas)												
TO TIC	Hallucinations												
ONC FOH NOI	Aggression (physical / verbal)												
SSPC	Anxiety												
MAY RESPOND TO ANTIPSYCHOTIC MEDICATIONS	Agitation (interferes with participation in daily activity / constant												
AA M	pacing / argumentative												
<u> </u>	Number of PRNs used												
	REPORTABLE SIDE EFFECTS (CHANGE FROM BASELINE)												
	Tardive Dyskinesia (e.g., involuntary movements, lip smacking, tongue thrusts, grimace)												
ING	Extrapyramidal symptoms (e.g., tremors, drooling, cogwheeling)												
S VRT	Dystonia (e.g., leaning, spasms, twitches)												
ECT STA IG D	Agitation												
PER IGIN VSI	Dehydration												
DE I AFI HAN PH		Drowsiness / Sedation											
	Dry mouth												
IMPORTANT SIDE EFFECTS OR INCREASED AFTER STAR DICATION OR CHANGING DO ** REPORT TO PHYSICIAN	Confusion												
IMPORTANT SIDE EFFECTS (NEW OR INCREASED AFTER STARTING MEDICATION OR CHANGING DOSE) ** REPORT TO PHYSICIAN	Excessive or Unnecessary disability (e.g., decline in function)												
MPC DR I ICA'	Cerebral Vascular Accident / TIA												
II SW (	Falls												
Z Z	Orthostatic Hypotension												
	Constipation  Wish Cair (position to particular)												
7 111 1 6	Weight Gain (weight monthly in kg)												
Initial of	PROFESSIONAL NURSE												
	PHYSICIAN/PRESCRIBER												
	PHARMACIST												

#### **STEP 4: Maintenance Record**

Documentation of the ongoing monitoring is tracked here. This will provide the physician with information to complete the required monthly assessment. This section is a continuation of Step 3 and the items being assessed are exactly the same.

One new item to be measured it the number of PRNs used in the time period being assessed. This shall be entered as a numeric value.

**Note:** The scoring has changed. (It is no longer "Y" or "N"). It will be scored as behavior that best reflects the frequency of behaviors and side-effects occurring over the 30 days prior to the day being scored.

- **0** behavior/side effect did not occur.
- 1 behavior/side effect occurred once.
- **2** behavior/side effects present more than once but less than every day.
- 3 behavior/side effects present daily.
- 4 behavior/side effects present more than once daily.

Enter a numeric value from 0 through 4 in **EVERY** box.

\*Documentation of the presence of a particular behavior or side-effect on the BSMT *does not replace* regular documentation in the progress record. Complete documentation of assessments is still required. One column should be dated and completed each month.

The BSMT and all other mapping tools used will become part of the patient's / resident's permanent record.